Centenial Surgical Suture Ltd
₹ 134
-4.96%
11 Jun
- close price
About
Incorporated in 1995, Centenial Surgical Suture Ltd is engaged in manufacturing of surgical sutures & other medical devices.
Key Points
- Market Cap ₹ 48.9 Cr.
- Current Price ₹ 134
- High / Low ₹ 170 / 82.2
- Stock P/E
- Book Value ₹ 84.3
- Dividend Yield 0.00 %
- ROCE 4.35 %
- ROE -4.64 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.76% over past five years.
- Company has a low return on equity of 0.60% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
50.96 | 51.71 | 51.39 | 52.84 | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 53.52 | |
46.39 | 46.47 | 46.71 | 47.95 | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 47.25 | |
Operating Profit | 4.57 | 5.24 | 4.68 | 4.89 | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.40 | 5.15 | 6.27 |
OPM % | 8.97% | 10.13% | 9.11% | 9.25% | 8.48% | 9.65% | 10.66% | 13.84% | 10.11% | 8.36% | 10.06% | 11.72% |
0.04 | 0.10 | 0.02 | 0.01 | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.12 | |
Interest | 1.31 | 1.61 | 1.65 | 1.77 | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 3.75 |
Depreciation | 0.59 | 0.83 | 0.68 | 0.59 | 0.60 | 0.69 | 1.55 | 1.55 | 1.53 | 1.30 | 1.39 | 4.25 |
Profit before tax | 2.71 | 2.90 | 2.37 | 2.54 | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | -1.61 |
Tax % | 33.95% | 34.14% | 34.18% | 32.68% | 36.10% | 29.12% | 39.81% | 37.25% | 42.06% | 39.73% | 11.02% | -9.32% |
1.79 | 1.92 | 1.56 | 1.72 | 1.54 | 2.02 | 1.30 | 0.96 | 0.63 | 0.89 | 1.13 | -1.46 | |
EPS in Rs | 4.91 | 5.26 | 4.28 | 4.71 | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.10 | -4.00 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -1% |
3 Years: | 6% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -229% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 33% |
3 Years: | 41% |
1 Year: | 21% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 1% |
3 Years: | 1% |
Last Year: | -5% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
Reserves | 13.83 | 15.79 | 17.35 | 19.07 | 20.62 | 22.63 | 23.18 | 24.15 | 24.77 | 25.66 | 26.79 | 25.33 |
11.32 | 12.28 | 13.11 | 15.24 | 14.37 | 13.10 | 12.72 | 13.47 | 9.30 | 9.92 | 23.24 | 12.26 | |
19.53 | 21.80 | 16.68 | 16.07 | 14.89 | 15.61 | 27.96 | 27.00 | 21.85 | 25.40 | 23.70 | 41.57 | |
Total Liabilities | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.58 |
4.53 | 4.13 | 3.64 | 3.71 | 3.80 | 4.08 | 10.44 | 8.97 | 7.60 | 6.46 | 12.77 | 19.99 | |
CWIP | 0.19 | 0.19 | 0.19 | 0.19 | 0.22 | 0.22 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
45.38 | 50.97 | 48.73 | 51.90 | 51.28 | 52.46 | 58.62 | 61.07 | 53.74 | 59.94 | 66.38 | 64.59 | |
Total Assets | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 84.58 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.25 | 0.21 | -1.51 | 0.00 | 1.76 | 1.55 | 2.08 | 1.97 | 4.75 | 1.30 | 6.21 | 17.07 | |
-0.42 | -0.36 | -0.19 | -2.38 | -0.64 | -1.02 | -1.31 | -0.89 | -0.17 | -0.18 | -7.92 | -11.61 | |
-1.34 | 0.96 | 0.82 | 2.14 | -0.88 | -1.27 | -0.37 | -1.27 | -4.87 | -1.05 | 2.06 | -5.93 | |
Net Cash Flow | -2.01 | 0.80 | -0.88 | -0.25 | 0.24 | -0.75 | 0.40 | -0.18 | -0.28 | 0.07 | 0.35 | -0.47 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 135.08 | 138.21 | 132.75 | 130.76 | 125.29 | 134.80 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 | 125.49 |
Inventory Days | 297.67 | 350.07 | 365.93 | 468.59 | 465.89 | 434.68 | 483.86 | 1,276.44 | 599.23 | 677.26 | 909.72 | 921.61 |
Days Payable | 162.36 | 167.34 | 124.26 | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159.00 | 222.42 | 207.75 | 151.98 |
Cash Conversion Cycle | 270.39 | 320.94 | 374.42 | 453.06 | 455.54 | 449.22 | 449.14 | 1,125.08 | 600.67 | 597.56 | 836.02 | 895.12 |
Working Capital Days | 187.94 | 205.48 | 233.39 | 156.25 | 164.05 | 167.69 | 172.36 | 403.64 | 313.08 | 276.49 | 329.63 | 294.41 |
ROCE % | 13.25% | 14.08% | 11.59% | 11.40% | 9.78% | 11.62% | 10.84% | 8.65% | 7.27% | 8.03% | 8.07% | 4.35% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 30 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Annual Secretarial Compliance Report for FY ended March 31, 2025, confirming regulatory adherence.
- Standalone Audited Financial Results For The Quarter And Year Ended March 31, 2025 28 May
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On May 28, 2025 Pursuant To Regulation 30 Of The SEBI (LODR [LODR]) Regulations, 2015.
28 May - Approved standalone audited financial results FY ended March 31, 2025 with unmodified auditor opinion.
-
Board Meeting Intimation for Approval Of Standalone Audited Financial Results For The Quarter And Year Ended March 31, 2025 As Per Regulation 33 Of The SEBI (LODR) Regulations, 2015
23 May - Board meeting on May 28, 2025, to approve audited financial results for FY and quarter ended March 31, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
Company manufactures highly specialized absorbable and non-absorbable sutures (cardio vascular sutures and atraumatic needled sutures) that are primarily used in CABG surgeries, and other medical devices. It sells products under:
a) Absorbable Sutures:[1]
Consists of Natural Sutures with brand names like Centenial -Catgut Plain and Centenial-Catgut Chromic in addition to Synthetic Sutures, with brand names like Centicryl, Monosynth and Centisorb
b) Non Absorbable Sutures:[2]
Brand names like Centilene, Centlon Centisilk, Centlinen, Centibond, Centsteel, Centidene
c) Medical Devices:[3]
T-suit, Centilene Mesh, Skin Stapler, Centiclip, Aortic Punch and KNIFE which is a Cardiovascular Vessel Knife